Hemogenyx Pharmaceuticals (HEMO.L) Continues To Work On Submitting An Application For A Study An Antibody To CDX

Today, the share price fell by 6.32%, the shares are trading at the price of 1,7800 GBP. Over the past 4 months, the company’s shares have been steadily falling. In April of this year, the share price was 7,5000 GBP. In the following month, the share price fell by 2.1750 GBP. In June, the shares were worth 2,0500. Today, the share price is 1,7800 GBP.HemoGenyx Pharmaceuticals has been continuously working to present a new research drug for the biopharmaceutical company’s leading product candidate, CDX antibodies, since it presented its results for the year ended December 31, 2018.

At the end of 2018, the group had cash and cash equivalents in the amount of 1,762 million pounds, which is slightly less than 1,877 million pounds a year earlier. As usual for a company developing new products, in 2018 Hemogenyx recorded a loss due to shareholders of 1.477 million pounds, which is significantly less than the loss of 2.361 million pounds that it posted a year earlier.

Paul Meyer

Part-Time Reporter. Paul could do better in his engineering profession where he became a real pro. However, he chose the finance field to find a tranquil environment in his career. Today he creates a good number of great content for our team.

Want Hot Stocks?    Yes. I Love Them No thanks